Third, unlike early RCTs, which administered G-CSF 24 hours postchemotherapy, this pragmatic study allowed for administration within 24-72 hours, a common real-world practice that may impact neutropenia duration and clinical outcomes.27 The gene discussed is CSF3; the disease is neutropenia.